This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To explore the use of human neural progenitor stem cells (HNPSCs) genetically modified to deliver the trophic factor GDNF as a therapy for Parkinson's disease. HNPSCs have been proposed as a source of cells for ex vivo gene therapy. In the past year we have performed a pilot study using HNPSCs genetically modified to deliver the trophic factor GDNF to assess viability and safety in the monkey brain. Our results showed that hNPCs releasing GDNF may be a possible alternative for GDNF delivery in Parkinson s disease. The data is currently being summarized for publication. Based on this study a second project with extensive behavioral testing comparing the effects of lentiviral vectors delivering GDNF vs HNPSCs delivering GDNF vs. HNPSCs alone vs. control media has started. This research used WNPRC Animal Services and Stem Cell Resources.
Showing the most recent 10 out of 528 publications